Biomarkers in hepatocellular carcinoma: an overview

References

• Abdel-Rahman O, Lamarca A, Valle JW, et al. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer. 2014;21(6):R485–R493.
   PubMed Web of Science ®Google Scholar
• Rota Caremoli E, Labianca R. Tivantinib: critical review with a focus on hepatocellular carcinoma. Expert Opin Investig Drugs. 2014;23(11):1563–1574.
   PubMed Web of Science ®Google Scholar
• Safety WIPoC. Biomarkers in risk assessment. Validity and validation. World Health Organization; 2001.
   Google Scholar
• Giannelli G, Rani B, Dituri F, et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut. 2014;63(10):1668–1676.
   PubMed Web of Science ®Google Scholar
• Zhang D, Wang Y, Dai Y. et al. Downregulation of RIP140 in hepatocellular carcinoma promoted the growth and migration of the cancer cells. Tumour Biol. 2015;36(3):2077–2085.
   PubMed Web of Science ®Google Scholar
• Bai XL, Zhang Q, Ye LY. et al. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling. Oncogene. 2015;34(31):4089–4097.
   PubMed Web of Science ®Google Scholar
• Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clinical Cancer Res. 2006;12(12):3657–3660.
   PubMed Web of Science ®Google Scholar
• Berger SL, Kouzarides T, Shiekhattar R, et al. An operational definition of epigenetics. Genes Dev. 2009;23(7):781–783.
   PubMed Web of Science ®Google Scholar
• Li J, Jin H, Wang X. Epigenetic biomarkers: potential applications in gastrointestinal cancers. ISRN Gastroenterol. 2014;464015:2014.
   Google Scholar
• Kanherkar RR, Bhatia-Dey N, Makarev E, et al. Cellular reprogramming for understanding and treating human disease. Front Cell Dev Biol. 2014;2:67.
   PubMed Web of Science ®Google Scholar
• Quint K, Agaimy A, Di Fazio P, et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Archiv. 2011;459(2):129–139.
   PubMed Web of Science ®Google Scholar
• Zhao JX, Yue WF, Zhu MJ, et al. AMP-activated protein kinase regulates beta-catenin transcription via histone deacetylase 5. J Biol Chem. 2011;286(18):16426–16434.
   PubMed Web of Science ®Google Scholar
• Enache LS, Enache EL, Ramiere C, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci. 2014;15(10):17644–17666.
   PubMed Web of Science ®Google Scholar
• Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2(2):e000825.
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167–175.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H, Nishida N, Calin GA, et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014;11(3):145–156.
   PubMed Web of Science ®Google Scholar
• Butt AN, Swaminathan R. Overview of circulating nucleic acids in plasma/serum. Ann N Y Acad Sci. 2008;1137:236–242.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49(5):1571–1582.
   PubMed Web of Science ®Google Scholar
• Oksuz Z, Serin MS, Kaplan E. et al. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep. 2015;42(3):713–720.
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–4788.
   PubMed Web of Science ®Google Scholar
• Yang L, Inokuchi S, Roh YS, et al. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology. 2013;144(5):1042–1054e1044.
   PubMed Web of Science ®Google Scholar
• Cheng HY, Kang PJ, Chuang YH, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. Plos One. 2014;9(11):e95870.
   PubMed Web of Science ®Google Scholar
• Joska TM, Zaman R, Belden WJ. Regulated DNA methylation and the circadian clock: implications in cancer. Biology (Basel). 2014;3(3):560–577.
   PubMedGoogle Scholar
• Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56.
   PubMed Web of Science ®Google Scholar
• Mah WC, Lee CG. DNA methylation: potential biomarker in hepatocellular carcinoma. Biomarker Res. 2014;2(1):5.
   PubMedGoogle Scholar
• Hinrichsen I, Kemp M, Peveling-Oberhag J, et al. Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. Plos One. 2014;9(1):e84453.
   PubMed Web of Science ®Google Scholar
• Zang JJ, Xie F, Xu JF, et al. P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2011;17(25):3043–3048.
   PubMed Web of Science ®Google Scholar
• Gao Y, He Y, Ding J. et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3ʹ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30(12):2064–2069.
   PubMed Web of Science ®Google Scholar
• Aleksandrova K, Boeing H, Nothlings U, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology. 2014;60(3):858–871.
   PubMed Web of Science ®Google Scholar
• Fujimoto A, Furuta M, Totoki Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016;48(5):500–509.
   PubMed Web of Science ®Google Scholar
• Liu G, Dong C, Integrated multiple LL. “-omics” data reveal subtypes of hepatocellular carcinoma. Plos One. 2016;11:(11), e0165457.
   Google Scholar
• Manini MA, Sangiovanni A, Fornari F, et al. Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma. J Hepatol. 2014;60(5):995–1001.
   PubMed Web of Science ®Google Scholar
• Hussain HK, Barr DC, Wald C. Imaging techniques for the diagnosis of hepatocellular carcinoma and the evaluation of response to treatment. Semin Liver Dis. 2014;34(4):398–414.
   PubMed Web of Science ®Google Scholar
• Kim BK, Kim KA, An C. et al. Prognostic role of magnetic resonance imaging versus computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int. 2015;35(6):1722–1730.
   PubMed Web of Science ®Google Scholar
• Inchingolo R, De Gaetano AM, Curione D. et al. Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. Eur Radiol. 2015;25(4):1087–1096.
   PubMed Web of Science ®Google Scholar
• Jain S, Xie L, Boldbaatar B. et al. Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol Res. 2015;45(11):1110–1123.
   PubMed Web of Science ®Google Scholar
• Fornari F, Ferracin M, Trere D, et al. Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. Plos One. 2015;10(10):e0141448.
   PubMed Web of Science ®Google Scholar
• Wang H, Hou L, Li A, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014;864894:2014.
   Google Scholar
• Morales RE, Shoushtari AN, Walsh MM, et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3:22.
   PubMed Web of Science ®Google Scholar
• Meguro M, Mizuguchi T, Nishidate T, et al. Prognostic roles of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol. 2015;21(16):4933–4945.
   PubMed Web of Science ®Google Scholar
• Ilikhan SU, Bilici M, Sahin H, et al. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol. 2015;21(22):6999–7007.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Hosaka T, Ikeda K, et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res. 2011;41(11):1036–1045.
   PubMed Web of Science ®Google Scholar
• Oyama K, Koda M, Sugihara T, et al. Rapid and early alpha-fetoprotein and des-gamma-carboxy prothrombin responses to initial arterial infusion chemotherapy predict treatment outcomes of advanced hepatocellular carcinoma. Mol Clin Oncol. 2015;3(3):655–662.
   PubMed Web of Science ®Google Scholar
• Cui SX, Zhang YS, Chu JH, et al. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells. Cell Physiol Biochem. 2015;35(1):201–212.
   PubMed Web of Science ®Google Scholar
• Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res. 2016;46(3):E130–135.
   PubMed Web of Science ®Google Scholar
• Shi M, Chen MS, Sekar K, et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer. 2014;50(5):928–936.
   PubMed Web of Science ®Google Scholar
• Lao X, Wang X, Liu Y, et al. Association of paraoxonase 1 gene polymorphisms with the risk of hepatitis B virus-related liver diseases in a Guangxi population: a case-control study. Medicine. 2015;94(48):e2179.
   PubMed Web of Science ®Google Scholar
• Abdel Wahab AH, El-Halawany MS, Emam AA, et al. Identification of circulating protein biomarkers in patients with hepatocellular carcinoma concomitantly infected with chronic hepatitis C virus. Biomarkers. 2016 Nov 10:1–8. doi: 10.1080/1354750X.2016.1252966. [Epub ahead of print].
   Google Scholar
• Ferrin G, Rodriguez-Peralvarez M, Aguilar-Melero P, et al. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. Plos One. 2015;10(3):e0118527.
   Web of Science ®Google Scholar
• Zhang S, Jiang K, Zhang Q, et al. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index. Glycoconj J. 2015;32(3–4):119–125.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–829.
   PubMed Web of Science ®Google Scholar
• Agwa ES, Ma PC. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib. Cancer Manag Res. 2014;6:397–404.
   PubMed Web of Science ®Google Scholar
• Santoro A, Simonelli M, Rodriguez-Lope C, et al. A phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer. 2013;108(1):21–24.
   PubMed Web of Science ®Google Scholar
• Borisov NM, Terekhanova NV, Aliper AM. et al. Signaling pathway activation profiles make better markers of cancer than expression of individual genes. Oncotarget. 2014 Aug 23. pii: 235.
   Google Scholar
• Park JW, Amarapurkar D, Chao Y, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33(3):327–337.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry A, Melero I, Crocenzi T, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040). J Clin Oncol. 2015;33(supp):abstr LBA101.
   Google Scholar
• Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588–610.
   PubMed Web of Science ®Google Scholar
• Wu XZ. New strategy of antiangiogenic therapy for hepatocellular carcinoma. Neoplasma. 2008;55(6):472–481.
   PubMed Web of Science ®Google Scholar
• Ciou SC, Chou YT, Liu YL. et al. Ribose-5-phosphate isomerase a regulates hepatocarcinogenesis via PP2A and ERK signaling. Int J Cancer. 2015;137(1):104–115.
   PubMed Web of Science ®Google Scholar
• Parihar JS, Tunuguntla HS. Role of chemokines in renal cell carcinoma. Rev Urol. 2014;16(3):118–121.
   PubMedGoogle Scholar
• Maishi N, Ohga N, Hida Y, et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int. 2012;62(5):309–317.
   PubMed Web of Science ®Google Scholar
• Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203(9):2201–2213.
   PubMed Web of Science ®Google Scholar
• D’Alterio C, Consales C, Polimeno M, et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr Cancer Drug Targets. 2010;10(7):772–781.
   PubMed Web of Science ®Google Scholar
• Xue TC, Jia QA, Bu Y, et al. CXCR7 correlates with the differentiation of hepatocellular carcinoma and suppresses HNF4alpha expression through the ERK pathway. Oncol Rep. 2014;32(6):2387–2396.
   PubMed Web of Science ®Google Scholar
• Xue TC, Chen RX, Ren ZG, et al. Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep. 2013;30(1):105–110.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zha TZ, Hu BS, et al. High expression of ADAM8 correlates with poor prognosis in hepatocellular carcinoma. Surgeon. 2013;11(2):67–71.
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang W, Li T. et al. Long noncoding RNA SNHG1 predicts a poor prognosis and promotes hepatocellular carcinoma tumorigenesis. Biomed Pharmacother. 2016;80:73–79.
   PubMed Web of Science ®Google Scholar
• Gu X, Fu M, Ge Z, et al. High expression of MAGE-A9 correlates with unfavorable survival in hepatocellular carcinoma. Sci Rep. 2014;4:6625.
   PubMed Web of Science ®Google Scholar
• Weeraratne SD, Amani V, Neiss A, et al. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011;13(2):165–175.
   PubMed Web of Science ®Google Scholar
• Bu Y, Liu F, Jia QA, et al. Decreased expression of TMEM173 predicts poor prognosis in patients with hepatocellular carcinoma. Plos One. 2016;11(11):e0165681.
   Web of Science ®Google Scholar
• Li Y, Xu KS, Li JS, et al. The research of no-touch isolation technique on the prevention of postoperative recurrence and metastasis of hepatocellular carcinoma after hepatectomy. Hepato Gastroenterol. 2014;61(131):784–791.
   PubMed Web of Science ®Google Scholar
• Pommergaard HC, Burcharth J, Rosenberg J, et al. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando). 2016;30(3):171–177.
   PubMedGoogle Scholar
• Liao W, Huang G, Liao Y, et al. High KIF18A expression correlates with unfavorable prognosis in primary hepatocellular carcinoma. Oncotarget. 2014;5(21):10271–10279.
   PubMed Web of Science ®Google Scholar
• Harada K, Baba Y, Ishimoto T, et al. LINE-1 methylation level and patient prognosis in a database of 208 hepatocellular carcinomas. Ann Surg Oncol. 2015;22(4):1280–1287.
   PubMed Web of Science ®Google Scholar
• Chen JD, Xiong YQ, Dong K, et al. Clinical significance of joint detection of serum VEGF, SIL-2R and HGF in patients with primary hepatocellular carcinoma before and after percutaneous microwave coagulation therapy. Asian Pac J Cancer Prev. 2014;15(11):4545–4548.
   PubMedGoogle Scholar
• Casadei Gardini A, Marisi G, Faloppi L, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016;7(19):27988–27999.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Faloppi L, Svegliati Baroni G, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135(5):1247–1256.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Rosmorduc O, et al. Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial. Clinical Cancer Res. 2016;22(19):4870–4879.
   PubMed Web of Science ®Google Scholar
• Musilova K, Mraz M. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2015;29(5):1004–1017.
   PubMed Web of Science ®Google Scholar
• Yang L, Ren Y, Pan W, et al. A novel fluorescent nanocomposite for visualizing cross-talk between microRNA-21 and hydrogen peroxide in ischaemia-reperfusion injury in live cells and in vivo. Anal Chem. 2016;88:11886–11891.
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Ishimaru Y, Kawasaki H, et al. AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology. 2015;89(3):167–174.
   PubMed Web of Science ®Google Scholar
• Murata K, Suzuki H, Okano H, et al. Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 2010;36(1):161–170.
   PubMed Web of Science ®Google Scholar
• Walesky C, Apte U. Role of hepatocyte nuclear factor 4alpha (HNF4alpha) in cell proliferation and cancer. Gene Expr. 2015;16(3):101–108.
   PubMed Web of Science ®Google Scholar
• Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67(6):705–712.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang C, Jiao X, et al. miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFkappaB. Am J Transl Res. 2016;8(11):4764–4777.
   PubMed Web of Science ®Google Scholar
• Okajima W, Komatsu S, Ichikawa D. et al. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function. Oncotarget. 2016;7(33):53820–53836.
   PubMed Web of Science ®Google Scholar